淋巴细胞功能相关抗原1/细胞间黏附分子在眼干燥症中的发病机制及免疫抑制相关药物的研究进展

doi:10.20047/j.issn1673-7210.2023.24.08

Abstract
Figure/Table
References (35)
Related Citation (15)

Download: PDF (482 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Lymphocyte function-associated antigen 1(LFA-1) and intercellular adhesion molecule (ICAM-1) are homologous ligands, the interaction of LFA-1/ICAM-1 is crucial for the proliferation and infiltration of immune cells. The pathogenesis of ophthalmoxerosis has afferent arm and efferent arm two pathways. The afferent arm refers to the transfer of antigen presenting cells to lymph nodes after being stimulated by the ocular surface; the efferent arm refers to the transfer of activated lymphocytes from lymph nodes to the ocular surface. LFA-1/ICAM-1 plays an important role in both the afferent and efferent arms, and is important for the diagnosis and treatment of diseases related to immune homeostasis destruction. The drugs of Lifitegrast, corticosteroids, and cyclosporine A used to ophthalmoxerosis from the perspective of immunopathology have achieved clinical results. This article reviews the pathogenesis of LFA-1/ICAM-1 in ophthalmoxerosisand the research progress of immunosuppressive drugs.

Key words： Ophthalmoxerosis Lymphocyte function-associated antigen 1 Intercellular adhesion molecule Lymphocyte cell Ocular immune response

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	SHA Yongyi KONG Xueqing XIANG Minhong

Cite this article:

SHA Yongyi KONG Xueqing XIANG Minhong. Research progress in pathogenesis of lymphocyte function-associated antigen 1/intercellular adhesion molecule in ophthalmoxerosis and immun- osuppressive drugs[J]. 中国医药导报, 2023, 20(24): 36-39.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.24.08 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I24/36

[1] Zemanova M. Dry Eye Disease. A Review [J]. Cesk Slov Oftalmol，2021，77（3）：107-119.
[2] Mittal R，Patel S，Galor A. Alternative therapies for dry eye disease [J]. Curr Opin Ophthalmol，2021，32（4）：348-361.
[3] Papas EB. The global prevalence of dry eye disease：A Bay- esian view [J]. Ophthalmic Physiol Opt，2021，41（6）：1254- 1266.
[4] Wan L，Zhou QJ，Xie LX. Research progress on the pathogenesis of diabetes-related dry eye [J]. Zhonghua Yan Ke Za Zhi，2022，58（12）：1099-1105.
[5] Bjordal O，Norheim KB，Rodahl E，et al. Primary Sjogren’s syndrome and the eye [J]. Surv Ophthalmol，2020，65（2）：119-132.
[6] Magno MS，Utheim TP，Snieder H，et al. The relationship between dry eye and sleep quality [J]. Ocul Surf，2021，20：13- 19.
[7] Vieira GCF，Rodrigues BRO，Cunha C，et al. Depression and dry eye：a narrative review [J]. Rev Assoc Med Bras （1992），2021，67（3）：462-467.
[8] Periman LM，Perez VL，Saban DR，et al. The Immunological Basis of Dry Eye Disease and Current Topical Treatment Options [J]. J Ocul Pharmacol Ther，2020，36（3）：137-146.
[9] Bui TM，Wiesolek HL，Sumagin R. ICAM-1：A master regulator of cellular responses in inflammation，injury resolution，and tumorigenesis [J]. J Leukoc Biol，2020，108（3）：787- 799.
[10] Hsueh PY，Ju Y，Vega A，et al. A Multivalent ICAM-1 Binding Nanoparticle which Inhibits ICAM-1 and LFA-1 Interaction Represents a New Tool for the Investigation of Autoimmune-Mediated Dry Eye [J]. Int J Mol Sci，2020，21（8）：2758.
[11] Walling BL，Kim M. LFA-1 in T Cell Migration and Differentiation [J]. Front Immunol，2018，9：952.
[12] Perez VL，Stern ME，Pflugfelder SC. Inflammatory basis for dry eye disease flares [J]. Exp Eye Res，2020，201：108294.
[13] Wang T，Li W，Cheng H，et al. The Important Role of the Chemokine Axis CCR7-CCL19 and CCR7-CCL21 in the Pathophysiology of the Immuno-inflammatory Response in Dry Eye Disease [J]. Ocul Immunol Inflamm，2021，29（2）：266-277.
[14] Ghosh S，Feigelson SW，Montresor A，et al. CCR7 signalosomes are preassembled on tips of lymphocyte microvilli in proximity to LFA-1 [J]. Biophys J，2021，120（18）：4002- 4012.
[15] Qian J，Xu X，Ding J，et al. Newcastle disease virus-like particles induce DC maturation through TLR4/NF-kappaB pathway and facilitate DC migration by CCR7-CCL19/ CCL21 axis [J]. Vet Microbiol，2017，203：158-166.
[16] Pflugfelder SC，Stern M，Zhang S，et al. LFA-1/ICAM-1 Interaction as a Therapeutic Target in Dry Eye Disease [J]. J Ocul Pharmacol Ther，2017，33（1）：5-12.
[17] Ouyang W，Wu Y，Lin X，et al. Role of CD4+ T Helper Cells in the Development of BAC-Induced Dry Eye Syndrome in Mice [J]. Invest Ophthalmol Vis Sci，2021，62（1）：25.
[18] Jung YH，Ryu JS，Yoon CH，et al. Age-Dependent Distinct Distributions of Dendritic Cells in Autoimmune Dry Eye Murine Model [J]. Cells，2021，10（8）：1857.
[19] Wang S，Wang B，Shi Y，et al. Mechanosensation by endothelial PIEZO1 is required for leukocyte diapedesis [J]. Blood，2022，140（3）：171-183.
[20] Gao J，Morgan G，Tieu D，et al. ICAM-1 expression predisposes ocular tissues to immune-based inflammation in dry eye patients and Sjogrens syndrome-like MRL/LPR mice [J]. Exp Eye Res，2004，78（4）：823-835.
[21] Lotscher J，Marti ILAA，Kirchhammer N，et al. Magnesium sensing via LFA-1 regulates CD8+ T cell effector function [J]. Cell，2022，185（4）：585-602.e29.
[22] Wu X，Chen X，Ma Y，et al. Analysis of tear inflammatory molecules and clinical correlations in evaporative dry eye disease caused by meibomian gland dysfunction [J]. Int Ophthalmol，2020，40（11）：3049-3058.
[23] Stern ME，Gao J，Schwalb TA，et al. Conjunctival T-cell subpopulations in Sjogren’s and non-Sjogren’s patients with dry eye[J]. Invest Ophthalmol Vis Sci，2002，43（8）：2609- 2614.
[24] Du G，Du W，An Y，et al. Design，synthesis，and LFA-1/ICAM-1 antagonist activity evaluation of Lifitegrast analogues [J]. Med Chem Res，2022，31（4）：555-579.
[25] Singh PP，Yu C，Mathew R，et al. Meibomian gland dysfunction is suppressed via selective inhibition of immune responses by topical LFA-1/ICAM antagonism with lifitegrast in the allergic eye disease （AED） model [J]. Ocul Surf，2021，21：271-278.
[26] Li JX，Tsai YY，Lai CT，et al. Lifitegrast Ophthalmic Solution 5% Is a Safe and Efficient Eyedrop for Dry Eye Disease：A Systematic Review and Meta-Analysis [J]. J Clin Med，2022，11（17）：5014.
[27] Holland EJ，Luchs J，Karpecki PM，et al. Lifitegrast for the Treatment of Dry Eye Disease：Results of a Phase Ⅲ，Randomized，Double-Masked，Placebo-Controlled Trial （OPUS-3）[J]. Ophthalmology，2017，124（1）：53-60.
[28] Donnenfeld ED，Karpecki PM，Majmudar PA，et al. Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease：A 1-Year，Multicenter，Randomized，Placebo- Controlled Study [J]. Cornea，2016，35（6）：741-748.
[29] Liu SH，Saldanha IJ，Abraham AG，et al. Topical corticosteroids for dry eye [J]. Cochrane Database Syst Rev，2022， 10（10）：CD015070.
[30] Prinz J，Maffulli N，Fuest M，et al. Efficacy of Topical Administration of Corticosteroids for the Management of Dry Eye Disease：Systematic Review and Meta-Analysis [J]. Life （Basel），2022，12（11）：1932.
[31] Messmer EM，Ahmad S，Benitez del castillo JM，et al. Management of inflammation in dry eye disease：Recommendations from a European panel of experts [J]. Eur J Ophthalmol，2022，5； 11206721221141481.
[32] Guo H，Ju Y，Choi M，et al. Supra-lacrimal protein-based carriers for cyclosporine A reduce Th17-mediated autoimmunity in murine model of Sjogren’s syndrome [J]. Biomaterials，2022，283：121441.
[33] Peng W，Jiang X，Zhu L，et al. Cyclosporine A （0.05%） Ophthalmic Gel in the Treatment of Dry Eye Disease：A Multicenter，Randomized，Double-Masked，Phase Ⅲ，COSMO Trial [J]. Drug Des Devel Ther，2022，16：3183-3194.
[34] Guo H，Lee C，Shah M，et al. A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjogren’s syndrome [J]. J Control Release，2018，292：183-195.
[35] Chen D，Zhang S，Bian A，et al. Efficacy and safety of 0.05% cyclosporine ophthalmic emulsion in treatment of Chinese patients with moderate to severe dry eye disease：A 12-week，multicenter，randomized，double-masked，placebo-controlled phase Ⅲ clinical study [J]. Medicine （Baltimore），2019，98（31）：e16710.